Mental health care utilization among men with castration‐resistant prostate cancer receiving abiraterone or enzalutamide

Mental health care utilization among men with castration‐resistant prostate cancer receiving abiraterone or enzalutamide

Abstract Background Abiraterone and enzalutamide are castration‐resistant prostate cancer (CRPC) therapies with potentially distinct associations with mental health symptoms given their differing antiandrogen targets. Methods We used national Veterans Health Administration data to identify patients...

Full description

Bibliographic Details
Main Authors: Phoebe A. Tsao, Jennifer Burns, Kyle Kumbier, Jordan B. Sparks, Shami Entenman, Lindsey E. Bloor, Amy S. B. Bohnert, Ted A. Skolarus, Megan E. V. Caram
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:Cancer Medicine
Subjects:
abiraterone
anxiety
depression
enzalutamide
mental health
prostate neoplasms
Online Access:https://doi.org/10.1002/cam4.6237

Internet

https://doi.org/10.1002/cam4.6237

Similar Items